NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

NTT-002

Summary

NTT-002 is a nanoformulation of irinotecan-loaded mesoporous silica nanoparticles (MSNs) developed for the treatment of highly metastatic colorectal cancer. This advanced nanomedicine is designed to suppress both primary tumor growth and metastatic progression, offering a promising approach for treating aggressive cancers.

Advantages of NTT-002

• Maintains API in its active therapeutic form

• Enables tumor-targeted delivery with reduced systemic toxicity

• Demonstrates inhibition of cancer metastasis

• Significantly improves overall survival

Efficacy in Inhibiting Tumor Growth and Metastasis

100% of mice treated with NTT-002 survived to the end of the study, exhibiting complete tumor regression and no detectable metastases.

Details of MSN’s unique anti-metastatic activity are available in ACS Appl. Mater. Interfaces 2024, 16, 61787